Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.

Recs

1
Player Avatar zzlangerhans (99.70) Submitted: 4/23/2013 8:24:04 PM : Underperform Start Price: $2.30 LXRX Score: +16.40

If there's one thing recent history has told us about Lexicon, it's that a market cap of over a billion for their highly speculative pipeline will not hold. Lexicon has assets, to be sure, and at a market cap of 500 or even 600M in this frothy market you wouldn't be hearing anything about them from me. But LX4211 doesn't have a clear place in the rapidly evolving field of glycemic control, and progression to phase III is on hold as a partnership is awaited. Telotristat is in the early stages of what undoubtedly will be a long phase III trial for the narrow indication of carcinoid. If the last year's pattern holds, the share price will be well under 2 again before any positive catalysts emerge from the pipeline.

Featured Broker Partners


Advertisement